JP2018528182A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528182A5
JP2018528182A5 JP2018505739A JP2018505739A JP2018528182A5 JP 2018528182 A5 JP2018528182 A5 JP 2018528182A5 JP 2018505739 A JP2018505739 A JP 2018505739A JP 2018505739 A JP2018505739 A JP 2018505739A JP 2018528182 A5 JP2018528182 A5 JP 2018528182A5
Authority
JP
Japan
Prior art keywords
compound
formula
reacting
configuration
reacted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528182A (ja
JP6816106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045553 external-priority patent/WO2017024134A1/en
Publication of JP2018528182A publication Critical patent/JP2018528182A/ja
Publication of JP2018528182A5 publication Critical patent/JP2018528182A5/ja
Application granted granted Critical
Publication of JP6816106B2 publication Critical patent/JP6816106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505739A 2015-08-05 2016-08-04 6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法 Active JP6816106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201546P 2015-08-05 2015-08-05
US62/201,546 2015-08-05
PCT/US2016/045553 WO2017024134A1 (en) 2015-08-05 2016-08-04 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020213670A Division JP2021063097A (ja) 2015-08-05 2020-12-23 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Publications (3)

Publication Number Publication Date
JP2018528182A JP2018528182A (ja) 2018-09-27
JP2018528182A5 true JP2018528182A5 (enExample) 2019-09-19
JP6816106B2 JP6816106B2 (ja) 2021-01-20

Family

ID=56684781

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018505739A Active JP6816106B2 (ja) 2015-08-05 2016-08-04 6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法
JP2020213670A Pending JP2021063097A (ja) 2015-08-05 2020-12-23 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020213670A Pending JP2021063097A (ja) 2015-08-05 2020-12-23 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Country Status (8)

Country Link
US (1) US9751863B2 (enExample)
EP (1) EP3331866B1 (enExample)
JP (2) JP6816106B2 (enExample)
CN (1) CN108349933A (enExample)
AU (2) AU2016303614A1 (enExample)
CA (1) CA2993615A1 (enExample)
MX (1) MX365590B (enExample)
WO (1) WO2017024134A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3200800A1 (en) 2014-09-29 2017-08-09 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
MX381582B (es) 2015-10-15 2025-03-12 Celgene Corp Terapia de combinacion para el tratamiento de neoplasias malignas.
CA3001599A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017146795A1 (en) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
JP2019529534A (ja) 2016-09-07 2019-10-17 セルジーン コーポレイション 錠剤組成物
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS5170779A (ja) * 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinaguanamidoruino seiho
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
ATE130882T1 (de) 1990-07-12 1995-12-15 Ciba Geigy Ag Verfahren zur photochemischen und thermischen stabilisierung von polyamid-fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
HUE029020T2 (en) 2002-07-18 2017-02-28 Janssen Pharmaceutica Nv Substituted triazine kinase inhibitors
EP2152676B1 (en) 2007-04-30 2013-04-03 ProMetic BioSciences Inc. "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
LT2800743T (lt) * 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
ES2807582T3 (es) 2013-07-11 2021-02-23 Agios Pharmaceuticals Inc Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015017821A2 (en) 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3200800A1 (en) 2014-09-29 2017-08-09 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine

Similar Documents

Publication Publication Date Title
JP2021063097A5 (enExample)
Chakraborti et al. “On water’’promoted ullmann-type C–N bond-forming reactions: application to carbazole alkaloids by selective N-arylation of aminophenols
DK2958903T3 (en) METHOD OF PREPARING VORTIOXETIN
JP2009533369A5 (enExample)
JP2013525264A5 (enExample)
JP2013525265A5 (enExample)
EA201170809A1 (ru) Способ получения производных пиперазина
Chen et al. Meglumine: an efficient, biodegradable, and recyclable green catalyst for one-pot synthesis of functionalized dihydropyridines
Talukdar et al. Ullmann-Type N-, S-, and O-Arylation Using a Well-Defined 7-Azaindole-N-oxide (7-AINO)-Based Copper (II) Catalyst: Scope and Application to Drug Synthesis
JP2016503812A5 (enExample)
RU2011148584A (ru) Способ получения [4-(2-хлор-4-метокси-5-метилфенил)-5-метилтиазоло-2-ил]-[2-циклопропил-1-(3-фтор-4-метилфенил)-этил]-амина
Wu et al. Dual role of BrCF 2 CO 2 Et: difluorocarbene-enabled access to α-trifluoromethyl ketones from sulfoxonium ylides
ES2587942T3 (es) Compuestos de fenilimidazol
JP2018505179A5 (enExample)
NO20081859L (no) Fremgangsmate for fremstillingen av sartanderivater og mellomprodukter som er nyttige i slike fremgangsmater
CN111757870A (zh) 合成甲磺草胺的方法
JP2762430B2 (ja) アラルキルアミノピリミジン類の製法
CN110845423A (zh) 一种1,2-取代苯并咪唑类化合物的制备方法
ATE498617T1 (de) Verfahren zur herstellung einer 3-o- alkylascorbinsäure
CN104540818A (zh) 环烷醇衍生物制备方法及唑衍生物制备方法
JP3161690B2 (ja) 2−メルカプトイミダゾール縮合環化合物の製造法
CA2584789A1 (en) Method for the preparation of aripiprazole, and corresponding intermediates and their preparation
TW201429953A (zh) 吡唑化合物的結晶的製造方法
RU2446164C2 (ru) Способ получения 3-замещенных 1,2-бензизоксазол-5,6-дикарбонитрилов
CN109422748A (zh) 合成tnni3k抑制剂的方法